ADAP Stock: Adaptimmune Therapeutics plc Stock Price, Analysis & Insights
Get live adap stock price $0.08, comprehensive Adaptimmune Therapeutics plc stock analysis, charts, news, and expert forecast. Real-time adap stock data and investment insights.
Company Overview
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Company Information
- CEO
- Adrian G. Rawcliffe
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 506
Contact Information
- Website
- https://www.adaptimmune.com
- Address
- 60 Jubilee Avenue
- Country
- GB
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 21.13M market capitalization
- Trading Volume: 470.98M shares traded today
- Price Range: 52-week range of $0.04 - $1.09
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc (ADAP) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 21.13M, the company represents a significant player in its market. The stock is currently trading at $0.08 with a positivedaily change of 22.82%.
The company's 506 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -0.12, beta of 2.24, and 52-week price range from $0.04 to $1.09when evaluating investment opportunities.
Why Invest in Adaptimmune Therapeutics plc?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Adrian G. Rawcliffe
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.